Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable ...

TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a ...

Key limitations included nonstandardized diagnostic criteria, proxy-derived activity/symptom measures, recall bias for ...

Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher ...

COA's Nicolas Ferreyros discusses real-world survival data for community oncology, health system consolidation, and barriers ...

Projectiles such as grass, dirt, and rocks caused 77% of injuries, and eye protection, including eyeglasses, was documented ...

The FDA has approved olanzapine extended-release injectable suspension (Weltruza; Teva Pharmaceuticals), a once-monthly ...

For patients with a blood cancer, the choice of a chimeric antigen receptor (CAR) T-cell therapy or a bispecific antibody is rarely a simple one, explains Kerry Rogers, MD, associate professor at The ...

Kansteiner F. PhRMA launches new legal challenge as CMS brings 'most favored nation' pricing to Medicare Part B. Fierce ...

The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content ...

The number of people living with heart failure (HF) worldwide more than doubled between 1990 and 2023, reaching an estimated ...

Patients with early-onset, BRAF V600E–mutated metastatic colorectal cancer should receive combination therapy as soon as ...